HES5 and prostate cancer: These results clearly demonstrate that in addition to being an early event in prostate tumourigenesis HES5 methylation is a highly recurrent event in prostate cancer, suggesting potential as a specific disease marker and an early acquired (or selected) event in prostate tumourigenesis.